Janux Therapeutics, Inc. JANX
12.04 USD 0.00 (+0.00%)
At closeNov 11, 2026, 9:02 AM EST
12.28 +0.24 +1.96%
Pre-market · Nov 11, 9:02 AM ET
11.59 Day range 12.76
11.59 52-week range 35.34
- YTD
- -12.75%
- 1 year
- -56.36%
News
seekingalpha.com Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript Janux Therapeutics, Inc. ( JANX ) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy November 9, 2026 8:30 AM EST Company Participants David Campbell - President,…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com Janux Therapeutics Reports Initial Phase 1 JANX011 Data, Providing Clinical Validation For ARM Platform In Autoimmune Diseases A single 3 mg subcutaneous dose produced greater than 90% peripheral B-cell depletion in most participants, including two participants with B cells below the limit of detection, with B-cell…
businesswire.com Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial…
benzinga.com Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27 Truist Securities analyst Supawat Thongthip maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $26 to $27.
benzinga.com Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40 Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $36 to $40.
benzinga.com Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15 Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Underweight and raises the price target from $14 to $15.
zacks.com Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.39 per share a year ago.- benzinga.com Janux Therapeutics Q3 EPS $(0.34) Beats $(0.46) Estimate, Sales $9.290M Beat $7.746M Estimate Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 12.82 percent increase over losses of…
businesswire.com Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial…
benzinga.com Janux Therapeutics Doses First Patient In The Phase 1 Clinical Trial For JANX013, Its PSMA-Targeted Tumor-Activated CD28 Co-Stimulatory Bispecific, In Patients With Metastatic Castration-Resistant Prostate Cancer The program is initially being developed in combination with JANX007, with the goal of further enhancing the durability of anti-tumor immune responses through tumor-restricted CD28 co-stimulation.…
benzinga.com This Darden Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list. DRI, JANX, and more mentioned.- benzinga.com Wolfe Research Upgrades Janux Therapeutics to Outperform, Announces $23 Price Target Wolfe Research analyst Kalpit Patel upgrades Janux Therapeutics (NASDAQ:JANX) from Peer Perform to Outperform and announces $23 price target.
benzinga.com Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $55 Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $55.- benzinga.com Janux Therapeutics Q2 EPS $(0.35) Beats $(0.38) Estimate, Sales $10.267M Miss $16.493M Estimate Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 36.36 percent increase over losses of…
benzinga.com Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26 Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ:JANX) with a Buy rating and lowers Price Target of $26.- benzinga.com Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26 Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $30 to $26.
benzinga.com Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36 Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and lowers the price target from $45 to $36.- benzinga.com Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $58 Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $68 to $58.
- benzinga.com Jones Trading Maintains Buy on Janux Therapeutics, Lowers Price Target to $28 Jones Trading analyst Boris Peaker maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $50 to $28.
benzinga.com Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move Janux Therapeutics halts JANX008 after Phase 1a review, shifting focus to higher-priority programs despite limited but durable responses.- benzinga.com Janux Therapeutics Discontinues JANX008 Cancer Program To Prioritize Higher-Potential Pipeline Opportunities Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further…
- benzinga.com Barclays Downgrades Janux Therapeutics to Underweight, Lowers Price Target to $14 Barclays analyst Etzer Darout downgrades Janux Therapeutics (NASDAQ:JANX) from Overweight to Underweight and lowers the price target from $29 to $14.
- benzinga.com Janux Therapeutics Doses First Participant In Phase 1 Clinical Study Of JANX014 To Treat Metastatic Castration-Resistant Prostate Cancer Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first patient has been dosed…
- benzinga.com UBS Downgrades Janux Therapeutics to Neutral, Lowers Price Target to $15 UBS analyst David Dai downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Neutral and lowers the price target from $57 to $15.
benzinga.com Janux Therapeutics Nominates Development Candidate Under Collaboration, License Agreement With Bristol Myers Squibb Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development…- benzinga.com Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $100 Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $150 to $100.
- benzinga.com Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $68 Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $72 to $68.
- benzinga.com Janux Therapeutics Q4 EPS $(0.51) Beats $(0.64) Estimate Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.64) by 20.19 percent. This is a 41.67 percent decrease over losses of…
benzinga.com Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com Janux Therapeutics Announces Collaboration And Exclusive Worldwide License Agreement With Bristol Myers Squibb To Develop Undisclosed Tumor-Activated Therapeutics For Solid Tumors Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor…
- benzinga.com Clear Street Downgrades Janux Therapeutics to Hold, Lowers Price Target to $12 Clear Street analyst Kaveri Pohlman downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Hold and lowers the price target from $32 to $12.
- benzinga.com Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $30 Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $42 to $30.
- benzinga.com Janux Therapeutics Provides Phase 1 Update on EGFR-Targeted JANX008; The Program Has Initiated Expansion Cohorts To Enable Further Evaluation And Support Continued Dose Optimization Across Selected Solid Tumor Settings Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager…
- benzinga.com Barclays Maintains Overweight on Janux Therapeutics, Lowers Price Target to $29 Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $48 to $29.
benzinga.com Gold Down Over 1%; Signet Shares Fall After Q3 Results - benzinga.com Stifel Maintains Buy on Janux Therapeutics, Lowers Price Target to $38 Stifel analyst Bradley Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $46 to $38.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Janux Therapeutics Stock Hits 52-Week Low After Trial Update JANX stock hit 52-week low after releasing Phase 1 data for JANX007 in mCRPC. Encouraging efficacy and safety profile observed in trials.
benzinga.com Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings 
benzinga.com Applied Materials To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday - benzinga.com Clear Street Maintains Buy on Janux Therapeutics, Lowers Price Target to $32 Clear Street analyst Kaveri Pohlman maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $80 to $32.
- benzinga.com B of A Securities Maintains Buy on Janux Therapeutics, Lowers Price Target to $49 B of A Securities analyst Geoff Meacham maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $58 to $49.
benzinga.com Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - benzinga.com Cantor Fitzgerald Maintains Overweight on Janux Therapeutics, Lowers Price Target to $150 Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lowers the price target from $200 to $150.
benzinga.com Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Janux Therapeutics, Lowers Price Target to $45 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $70 to $45.
- benzinga.com Janux Therapeutics Data From Phase 1 Clinical Study Of JANX007 Demonstrates High Prostate-Specific Antigen Response Rates, Deep PSA Declines Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor…